Skip to content

Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting

Elena Argento, Steffanie A. Strathdee, Kenneth W. Tupper, Melissa Braschel, Evan Wood, Kate Shannon

BMJ Open September 1, 2017 DOI: 10.1136/bmjopen-2017-016025 via OpenAlex

Summary

AI-generated from the abstract

Among marginalised women in Vancouver, those who had ever used a psychedelic drug showed a 60% lower hazard of developing suicidal ideation or attempts over 54 months, after adjusting for other factors. Crystal methamphetamine use tripled the hazard, and childhood abuse more than tripled it. Nearly half of the 766 women had prior suicidality and were excluded; among the 290 without it at baseline, 11% developed suicidality during follow-up, an incidence of 4.42 per 100 person-years. The findings suggest naturalistic psychedelic use may have a protective association, while other illicit drug use and childhood trauma increase risk.

Study at a glance

Characteristics Longitudinal community-based cohort study Peer reviewed
Sample size 290
Population Marginalised women in Metro Vancouver, Canada, without suicidality at baseline
Duration 54-month follow-up
Keywords Suicidal ideation Psychiatry Hazard ratio Cohort study Longitudinal study
Citations 60
Key finding Lifetime psychedelic drug use was associated with a 60% reduced hazard for new suicidality (adjusted HR 0.40; 95% CI 0.17 to 0.94).

Abstract

Objective This study aimed to longitudinally investigate whether ever having used a psychedelic drug can have a protective effect on incidence of suicidality among marginalised women. Design Longitudinal community-based cohort study. Setting Data were drawn from a prospective, community-based cohort of marginalised women in Metro Vancouver, Canada. Participants 766 women completed the baseline questionnaire between January 2010 and August 2014. Participants who did not report suicidality at baseline and who completed at least one follow-up visit were included. Main outcome measure Extended Cox regression was used to model predictors of new suicidality (suicide ideation or attempts) over 54-month follow-up. Results Nearly half (46%; n=355) of participants reported prior suicidality and were thus excluded from the present analyses. Of 290 women eligible at baseline, 11% (n=31) reported recent suicidality during follow-up, with an incidence density of 4.42 per 100 person-years (95% CI 3.10 to 6.30). In multivariable analysis, reported lifetime psychedelic drug use was associated with a 60% reduced hazard for suicidality (adjusted HR (AHR) 0.40; 95% CI 0.17 to 0.94). Crystal methamphetamine use (AHR 3.25; 95% CI 1.47 to 7.21) and childhood abuse (AHR 3.54; 95% CI 1.49 to 8.40) remained independent predictors of suicidality. Conclusion The high rate of suicidality identified in this study is of major concern. Alongside emerging evidence on the potential of psychedelic-assisted therapy to treat some mental illness and addiction issues, our findings demonstrate that naturalistic psychedelic drug use is independently associated with reduced suicidality, while other illicit drug use and childhood trauma predispose women to suicidality. While observational, this study supports calls for further investigation of the therapeutic utility of psychedelic drugs in treating poor mental health and promoting mental wellness.

Comments

No comments yet.

Log in to comment